STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells

References

• Asnafi, A. A., Deris Zayeri, Z., Shahrabi, S., Zibara, K., & Vosughi, T. (2019). Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches. Journal of Cellular Physiology, 234(5), 5798–5806. https://doi.org/10.1002/jcp.27505
   PubMed Web of Science ®Google Scholar
• Berger, A., Sexl, V., Valent, P., & Moriggl, R. (2014). Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia. Oncotarget, 5(20), 9564–9576. https://doi.org/10.18632/oncotarget.2465
   PubMedGoogle Scholar
• Buettner, R., Mora, L. B., & Jove, R. (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 8(4), 945–954.
   PubMed Web of Science ®Google Scholar
• Cai, N. (2017). The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. American Journal of Translational Research, 9(8), 3853–3866.
   PubMed Web of Science ®Google Scholar
• Caldemeyer, L., Dugan, M., Edwards, J., & Akard, L. (2016). Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Current Hematologic Malignancy Reports, 11(2), 71–79. https://doi.org/10.1007/s11899-016-0309-2
   PubMed Web of Science ®Google Scholar
• Chan, O., Talati, C., Isenalumhe, L., Shams, S., Nodzon, L., Fradley, M., Sweet, K., & Pinilla-Ibarz, J. (2020). Side-effects profile and outcomes of Ponatinib in the treatment of chronic myeloid leukemia. Blood Advances, 4(3), 530–538. https://doi.org/10.1182/bloodadvances.2019000268
   PubMed Web of Science ®Google Scholar
• Dorer, D. J., Knickerbocker, R. K., Baccarani, M., Cortes, J. E., Hochhaus, A., Talpaz, M., & Haluska, F. G. (2016). Impact of dose intensity of Ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leukemia Research, 48, 84–91. https://doi.org/10.1016/j.leukres.2016.07.007
   PubMed Web of Science ®Google Scholar
• Fabbro, D. (2012). BCR-ABL signaling: A new STATus in CML. Nature Chemical Biology, 8(3), 228–229. https://doi.org/10.1038/nchembio.900
   PubMed Web of Science ®Google Scholar
• Hoelbl, A., Schuster, C., Kovacic, B., Zhu, B., Wickre, M., Hoelzl, M. A., Fajmann, S., Grebien, F., Warsch, W., Stengl, G., Hennighausen, L., Poli, V., Beug, H., Moriggl, R., & Sexl, V. (2010). Stat5 is indispensable for the maintenance of Bcr/Abl-positive leukaemia. EMBO Molecular Medicine, 2(3), 98–110. https://doi.org/10.1002/emmm.201000062
   PubMed Web of Science ®Google Scholar
• Jabbour, E., & Kantarjian, H. (2018). Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. American Journal of Hematology, 93(3), 442–459. https://doi.org/10.1002/ajh.25011
   PubMed Web of Science ®Google Scholar
• Jain, P., Kantarjian, H., Jabbour, E., Gonzalez, G. N., Borthakur, G., Pemmaraju, N., Daver, N., Gachimova, E., Ferrajoli, A., Kornblau, S., Ravandi, F., O'Brien, S., & Cortes, J. (2015). Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: A phase 2 study. The Lancet Haematology, 2(9), e376–e383. https://doi.org/10.1016/S2352-3026(15)00127-1
   PubMed Web of Science ®Google Scholar
• Johnston, A. N., Bu, W., Hein, S., Garcia, S., Camacho, L., Xue, L., Qin, L., Nagi, C., Hilsenbeck, S. G., Kapali, J., Podsypanina, K., Nangia, J., & Li, Y. (2018). Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Research, 20(1), 1–13. https://doi.org/10.1186/s13058-018-0969-z
   PubMedGoogle Scholar
• Jørgensen, H. G., & Holyoake, T. L. (2007). Characterization of cancer stem cells in chronic myeloid leukaemia. Biochemical Society Transactions, 35(Pt 5), 1347–1351. https://doi.org/10.1042/BST0351347
   PubMed Web of Science ®Google Scholar
• Kim, Y. D., Jeong, E. I., Nah, J., Yoo, S.-M., Lee, W. J., Kim, Y., Moon, S., Hong, S.-H., & Jung, Y.-K. (2017). Pimozide reduces toxic forms of tau in TauC3 mice via 5′ adenosine monophosphate-activated protein kinase-mediated autophagy. Journal of Neurochemistry, 142(5), 734–746. https://doi.org/10.1111/jnc.14109
   PubMed Web of Science ®Google Scholar
• Kosova, B., Tezcanli, B., Ekiz, H. A., Cakir, Z., Selvi, N., Dalmizrak, A., Kartal, M., Gunduz, U., & Baran, Y. (2010). Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leukemia & Lymphoma, 51(10), 1895–1901. https://doi.org/10.3109/10428194.2010.507830
   PubMed Web of Science ®Google Scholar
• Levy, D. E., & Darnell, J. E. (2002). STATs: Transcriptional control and biological impact. Nature Reviews. Molecular Cell Biology, 3(9), 651–662. https://doi.org/10.1038/nrm909
   PubMed Web of Science ®Google Scholar
• Lewis, R. S., & Ward, A. C. (2008). Stat5 as a diagnostic marker for leukemia. Expert Review of Molecular Diagnostics, 8(1), 73–82. https://doi.org/10.1586/14737159.8.1.73
   PubMed Web of Science ®Google Scholar
• Lu, L., Kok, C. H., Saunders, V. A., Wang, J., McLean, J. A., Hughes, T. P., & White, D. L. (2018). Modelling Ponatinib resistance in tyrosine kinase inhibitor-naïve and Dasatinib resistant BCR-ABL1+ cell lines. Oncotarget, 9(78), 34735–34747. https://doi.org/10.18632/oncotarget.26187
   PubMedGoogle Scholar
• Mitchell, R., Hopcroft, L. E. M., Baquero, P., Allan, E. K., Hewit, K., James, D., Hamilton, G., Mukhopadhyay, A., O'Prey, J., Hair, A., Melo, J. V., Chan, E., Ryan, K. M., Maguer-Satta, V., Druker, B. J., Clark, R. E., Mitra, S., Herzyk, P., Nicolini, F. E., … Helgason, G. V. (2018). Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition. Journal of the National Cancer Institute, 110(5), 467–478. https://doi.org/10.1093/jnci/djx236
   PubMedGoogle Scholar
• Mohanty, S. K., Yagiz, K., Pradhan, D., Luthringer, D. J., Amin, M. B., Alkan, S., & Cinar, B. (2017). STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget, 8(49), 85997–86010. https://doi.org/10.18632/oncotarget.20844
   PubMedGoogle Scholar
• Mughal, T. I., Radich, J. P., Deininger, M. W., Apperley, J. F., Hughes, T. P., Harrison, C. J., Gambacorti-Passerini, C., Saglio, G., Cortes, J., & Daley, G. Q. (2016). Chronic myeloid leukemia: Reminiscences and dreams. Haematologica, 101(5), 541–558. https://doi.org/10.3324/haematol.2015.139337
   PubMed Web of Science ®Google Scholar
• Nelson, E. A., Walker, S. R., Weisberg, E., Bar-Natan, M., Barrett, R., Gashin, L. B., Terrell, S., Klitgaard, J. L., Santo, L., Addorio, M. R., Ebert, B. L., Griffin, J. D., & Frank, D. A. (2011). The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood, 117(12), 3421–3429. The. https://doi.org/10.1182/blood-2009-11-255232
   PubMed Web of Science ®Google Scholar
• Nelson, E. A., Walker, S. R., Xiang, M., Weisberg, E., Bar-Natan, M., Barrett, R., Liu, S., Kharbanda, S., Christie, A. L., Nicolais, M., Griffin, J. D., Stone, R. M., Kung, A. L., & Frank, D. A. (2012). The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes & Cancer, 3(7–8), 503–511. https://doi.org/10.1177/1947601912466555
   PubMedGoogle Scholar
• Nie, Z. Y. (2020). De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to imatinib resistance. Journal of Experimental & Clinical Cancer Research, 39(1), 1–14. https://doi.org/10.1186/s13046-019-1502-7
   PubMed Web of Science ®Google Scholar
• O’Hare, T. (2009). AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16(5), 401–412. https://doi.org/10.1016/j.ccr.2009.09.028
   PubMed Web of Science ®Google Scholar
• Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004). The JAK/STAT signaling pathway. Journal of Cell Science, 117(Pt 8), 1281–1283. https://doi.org/10.1242/jcs.00963
   PubMed Web of Science ®Google Scholar
• Redaelli, S., Mologni, L., Rostagno, R., Piazza, R., Magistroni, V., Ceccon, M., Viltadi, M., Flynn, D., & Gambacorti-Passerini, C. (2012). Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. American Journal of Hematology, 87(11), E125–E128. https://doi.org/10.1002/ajh.23338
   PubMed Web of Science ®Google Scholar
• Rondanin, R., Simoni, D., Romagnoli, R., Baruchello, R., Marchetti, P., Costantini, C., Fochi, S., Padroni, G., Grimaudo, S., Pipitone, R. M., Meli, M., & Tolomeo, M. (2014). Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. Bioorganic & Medicinal Chemistry Letters, 24(18), 4568–4574. https://doi.org/10.1016/j.bmcl.2014.07.069
   PubMed Web of Science ®Google Scholar
• Roos, A., Dhruv, H. D., Peng, S., Inge, L. J., Tuncali, S., Pineda, M., Millard, N., Mayo, Z., Eschbacher, J. M., Loftus, J. C., Winkles, J. A., & Tran, N. L. (2018). EGFRvIII-Stat5 signaling enhances glioblastoma cell migration and survival. Molecular Cancer Research: MCR, 16(7), 1185–1195. https://doi.org/10.1158/1541-7786.MCR-18-0125
   PubMed Web of Science ®Google Scholar
• Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., Leclercq, T., Hughes, T. P., & White, D. L. (2015). Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 29(1), 76–85. https://doi.org/10.1038/leu.2014.156
   PubMed Web of Science ®Google Scholar
• Shet, A. S., Jahagirdar, B. N., & Verfaillie, C. M. (2002). Chronic myelogenous leukemia: Mechanisms underlying disease progression. Leukemia, 16(8), 1402–1411. https://doi.org/10.1038/sj.leu.2402577
   PubMed Web of Science ®Google Scholar
• Vainchenker, W., & Constantinescu, S. N. (2013). JAK/STAT signaling in hematological malignancies. Oncogene, 32(21), 2601–2613. https://doi.org/10.1038/onc.2012.347
   PubMed Web of Science ®Google Scholar
• Wang, D., Pan, H., & Wang, Y. (2017). T315L: A novel mutation within BCR-ABL kinase domain confers resistance against Ponatinib. Leukemia & Lymphoma, 58(7), 1733–1735. https://doi.org/10.1080/10428194.2016.1251591
   PubMed Web of Science ®Google Scholar
• Wongboonma, W., Thongnoppakhun, W., & Auewarakul, C. U. (2012). BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Experimental and Molecular Pathology, 92(2), 259–265. https://doi.org/10.1016/j.yexmp.2012.01.007
   PubMed Web of Science ®Google Scholar
• Yanagiya, R., Ishikawa, D., Toubai, T., Ichikawa, T., Kawaguchi, N., Sugasawa, K., Ishizawa, K., & Saito, S. (2020). A rare chromosome abnormality with der(16)t(1;16)(q12;q11.2) in blast crisis of chronic myeloid leukemia. Case Reports in Oncology, 13(2), 1020–1025. https://doi.org/10.1159/000509642
   PubMed Web of Science ®Google Scholar